3/3/2026, 7:32:02 AM
SAN DIEGO, CA — March 3, 2026 — Leads & Copy — Modular Medical, Inc. (NASDAQ:MODD), an insulin delivery technology company, announced the pricing of a public offering expected to generate approximately $12.0 million before deducting fees and expenses.
The offering involves 68,098,000 shares of common stock (or pre-funded warrants) and warrants to purchase up to 68,098,000 shares of common stock, offered to new and existing investors at a combined price of $0.1762 per share (or pre-funded warrant) and accompanying warrant. The warrants will be immediately exercisable at a price of $0.1762 per share and will expire five years from the date of issuance.
The company’s FDA-cleared patch pump targets adult “almost-pumpers” with a user-friendly and affordable design.
The offering is expected to close on or about March 4, 2026, pending customary closing conditions.
Maxim Group LLC is the sole placement agent for the offering.
The securities are being offered under a registration statement on Form S-1 (File No. 333-293842), declared effective by the SEC on March 3, 2026. The offering is made via a prospectus, with electronic copies available on the SEC’s website and from Maxim Group LLC.
Modular Medical, Inc. aims to launch the next generation of insulin delivery technology, using patented technologies to improve access to glycemic control for people with diabetes.
The company was founded by Paul DiPerna, who previously founded Tandem Diabetes and invented the t:slim insulin pump.
This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of securities in any jurisdiction where such an offer, solicitation, or sale would be unlawful prior to registration or qualification under securities laws.
Forward-looking statements in the release are subject to risks and uncertainties, as detailed in Modular Medical’s SEC filings.
Source: Modular Medical, Inc.
